Quarterly report pursuant to Section 13 or 15(d)

Reverse Merger - Additional Information (Detail)

v3.10.0.1
Reverse Merger - Additional Information (Detail)
$ / shares in Units, $ in Thousands
9 Months Ended 12 Months Ended
May 23, 2018
Aug. 01, 2017
Year
Right
$ / shares
shares
Jan. 05, 2017
Sep. 30, 2017
USD ($)
Dec. 31, 2017
USD ($)
shares
Sep. 30, 2018
shares
Business Acquisition [Line Items]            
Reverse stock split ratio 0.1          
Common stock, shares outstanding | shares         1,194,793 4,901,095
Contingent value rights recovery | $       $ 200 $ 200  
OncoGenex Pharmaceuticals, Inc [Member]            
Business Acquisition [Line Items]            
Reverse stock split ratio   0.0909 0.0909      
Share price | $ / shares   $ 46.20        
Common stock, shares outstanding | shares   273,670        
Number of non-transferable contingent value rights with potential cash and other consideration receivable right | Right   1        
OncoGenex Pharmaceuticals, Inc [Member] | Contingent Value Rights [Member]            
Business Acquisition [Line Items]            
Combined company acquisition period results   5 years        
Aggregate consideration distributed to the holders, consideration received percent   80.00%        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Price [Member] | Warrant [Member]            
Business Acquisition [Line Items]            
Fair value of outstanding warrants, assumptions   46.20        
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Minimum [Member]            
Business Acquisition [Line Items]            
Fair value of outstanding warrants, assumptions   1.32        
OncoGenex Pharmaceuticals, Inc [Member] | Risk-Free Interest [Member] | Warrant [Member] | Maximum [Member]            
Business Acquisition [Line Items]            
Fair value of outstanding warrants, assumptions   1.53        
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Minimum [Member]            
Business Acquisition [Line Items]            
Fair value of outstanding warrants, assumptions   1 year 10 months 28 days        
OncoGenex Pharmaceuticals, Inc [Member] | Expected Lives [Member] | Warrant [Member] | Maximum [Member]            
Business Acquisition [Line Items]            
Fair value of outstanding warrants, assumptions   3 years 2 months 26 days        
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Minimum [Member]            
Business Acquisition [Line Items]            
Fair value of outstanding warrants, assumptions   90.33        
OncoGenex Pharmaceuticals, Inc [Member] | Volatility [Member] | Warrant [Member] | Maximum [Member]            
Business Acquisition [Line Items]            
Fair value of outstanding warrants, assumptions   106.08        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Stock Price [Member]            
Business Acquisition [Line Items]            
Fair value of stock options, assumptions   46.20        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Minimum [Member]            
Business Acquisition [Line Items]            
Fair value of stock options, assumptions   97.23        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Volatility [Member] | Maximum [Member]            
Business Acquisition [Line Items]            
Fair value of stock options, assumptions   106.63        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Minimum [Member]            
Business Acquisition [Line Items]            
Fair value of stock options, assumptions   1.31        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Risk-Free Interest [Member] | Maximum [Member]            
Business Acquisition [Line Items]            
Fair value of stock options, assumptions   1.54        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Minimum [Member]            
Business Acquisition [Line Items]            
Fair value of stock options, assumptions | Year   1.82        
OncoGenex Pharmaceuticals, Inc [Member] | Stock Options [Member] | Expected Lives [Member] | Maximum [Member]            
Business Acquisition [Line Items]            
Fair value of stock options, assumptions | Year   3.31